Expect Questions About Trelegy for Asthma

November 2020

The "three-in-one" Trelegy Ellipta inhaler is now approved for ASTHMA...not just for COPD.

Trelegy contains the inhaled corticosteroid (ICS) fluticasone furoate...the long-acting beta-agonist (LABA) vilanterol...and the long-acting muscarinic antagonist (LAMA) umeclidinium.

Trelegy seems to improve lung function in asthma patients not controlled on a medium- or high-dose ICS/LABA...but isn't yet shown to reduce exacerbations.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote